The Host Response to Lesions Induced by Human Papillomavirus

  1. Derek J. Chadwick Organizer and
  2. Joan Marsh
  1. Margaret Stanley,
  2. Nicholas Coleman and
  3. Mark Chamberst

Published Online: 28 SEP 2007

DOI: 10.1002/9780470514672.ch3

Ciba Foundation Symposium 187 - Vaccines Against Virally Induced Cancers

Ciba Foundation Symposium 187 - Vaccines Against Virally Induced Cancers

How to Cite

Stanley, M., Coleman, N. and Chamberst, M. (2007) The Host Response to Lesions Induced by Human Papillomavirus, in Ciba Foundation Symposium 187 - Vaccines Against Virally Induced Cancers (eds D. J. Chadwick and J. Marsh), John Wiley & Sons, Ltd., Chichester, UK. doi: 10.1002/9780470514672.ch3

Author Information

  1. Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK

  1. Department of Histopathology, Addenbrooke's Hospital, Cambridge

  2. Department of Biochemistry, Imperial College, Kensington, London, UK

Publication History

  1. Published Online: 28 SEP 2007

ISBN Information

Print ISBN: 9780471950264

Online ISBN: 9780470514672

SEARCH

Keywords:

  • host response;
  • lesions;
  • human papillomavirus;
  • DTH responses;
  • delayed-type hypersensitivity response

Summary

Human papillomaviruses (HPVs) are strictly intraepithelial pathogens: in the natural productive infection they induce benign epithelial proliferations of mucocutaneous surfaces, some of which may progress to malignancy. Benign HPV-induced lesions are chronic persistent growths; high levels of viral antigen are expressed in the apparent absence of a host immune response suggesting that these viruses have evolved efficient mechanisms of immune evasion. Cell-mediated responses are central in the pathogenesis of HPV and regression of both cutaneous and genital warts histologically resembles a delayed-type hypersensitivity response (DTH). The antigen(s) in the wart against which this response is initiated are not known but in an experimental murine model DTH responses to the E6 and E7 proteins of HPV-16 can be elicited when viral antigen is presented via the epithelial route. Priming with low levels of viral antigen in this model induces non-responsiveness and the loss of DTH. In HPV-associated cancers the E6/E7 genes are expressed and an antibody response to the proteins is found in at least 50% of cases indicating that these oncoproteins are potential targets for immunotherapy.